CHARLES TOWN, W.Va., Aug. 27 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. today announced that it has negotiated an exclusive license from White Hall, Inc. for the micronized, amorphous silver ion technology to treat the highly contagious skin disease, Molluscum Contagiosum. ReBuilder Medical has been manufacturing and distributing this product since 2004 with a non-exclusive license.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
Molluscum Contagiosum appears as small warts, boils or pimples that have a translucent core. It is highly contagious and is transmitted sexually in adults. In children it is transmitted through play, swimming pools, shared towels and athletic equipment. Up to now there has been no cure for the disease.
Currently available treatments in doctor's offices include cutting, burning, or freezing off the lesions. This is very painful and leaves the patient open to opportunistic secondary bacterial infections. Prescription ointments are sometimes offered, but these can burn the surrounding skin, leaving this previously healthy tissue vulnerable to cross contamination.
Molluscum Contagiosum is growing quickly all around the world. Pediatricians have reported that approximately 10% of the new patients they see are diagnosed with this skin disease. White Hall, Inc. has developed a non invasive treatment (http://www.molluscum.com) that uses silver and a small battery powered device to stop the infection painlessly. ReBuilder Medical did the actual development work of this device under an R&D development contract.
"Now that we have observed the efficacy of the system," says Adeyemi Bandele, VP of ReBuilder Medical Technologies, Inc. "We feel that we can make significant improvements to this technology because of our our electronic engineering resources to simplify their design of their electronic accelerator unit and reduce the manufacturing cost. We also feel that we now have the distribution capability to take this consumer based product directly to the physicians in order to reach more users. So we are taking on the product as our own. Part of the license allows us to buy the technology outright in the future.
ReBuilder Medical Technologies, Inc. developed and markets the ReBuilder System for diabetic peripheral neuropathy, a painful nerve condition in the feet and legs.
ReBuilder Medical Technologies, Inc. asserts that the market potential for Molluscum Contagiosum treatments will increase its revenues by significantly in 2007.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical's flagship product is its FDA registered ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical product that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum virus without side effects. The company is currently performing research and development on a number of other products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the early detection of breast cancer and the AcuPen which detects acupuncture points and then treats them.
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comReBuilder Medical Technologies, Inc.CONTACT: David Phillips of ReBuilder Medical Technologies, Inc.,+1-304-725-2202
